Binh An P. Phan

Binh An P. Phan

Auto-generated profile, based on publicly available information

Binh An P. Phan

University of California San Francisco, Zuckerberg San Francisco General Hospital Division of Cardiology San Francisco, CA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in JACC
Verified
Journal Article
Closed access
PMPamela B. Morris
Pamela B. Morris
BFBrian A. Ference
Brian A. Ference
EJEiman Jahangir
Eiman Jahangir
DFDmitriy N. Feldman
Dmitriy N. Feldman
JRJohn J. Ryan
John J. Ryan
NBNeal L. Benowitz
Neal L. Benowitz

27 October 2015 in Circulation
Verified
Journal Article
Open access
PDF file
NBnathalie bergeron
nathalie bergeron
BPBinh An P. Phan
Binh An P. Phan
YDYunchen Ding
Yunchen Ding
AFAleyna Fong
Aleyna Fong
RKRon Krauss
Ron Krauss
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in the regulation of cholesterol homeostasis. By binding to hepatic low-density lipoprotein (LDL) receptors and promoting their lysosomal degradation, PCSK9 reduces LDL uptake, leading to an increase in LDL cholesterol concentrations. Gain-of-function mutations in PCSK9 associated with high LDL cholesterol and premature cardiovascular disease have been causally implicated in the pathophysiology of autosomal-dominant familial hypercholesterolemia. In contrast, the more commonly expressed loss-of-function mutations in PCSK9 are associated with reduced LDL cholesterol and cardiovascular disease risk. The development of therapeutic approaches that inhibit PCSK9 function has therefore attracted considerable attention from clinicians and the pharmaceutical industry for the management of hypercholesterolemia and its associated cardiovascular disease risk. This review summarizes the effects of PCSK9 on hepatic and intestinal lipid metabolism and the more recently explored functions of PCSK9 in extrahepatic tissues. Therapeutic approaches that prevent interaction of PCSK9 with hepatic LDL receptors (monoclonal antibodies, mimetic peptides), inhibit PCSK9 synthesis in the endoplasmic reticulum (antisense oligonucleotides, siRNAs), and interfere with PCSK9 function (small molecules) are also described. Finally, clinical trials testing the safety and efficacy of monoclonal antibodies to PCSK9 are reviewed. These have shown dose-dependent decreases in LDL cholesterol (44%–65%), apolipoprotein B (48%–59%), and lipoprotein(a) (27%–50%) without major adverse effects in various high-risk patient categories, including those with statin intolerance. Initial reports from 2 of these trials have indicated the expected reduction in cardiovascular events. Hence, inhibition of PCSK9 holds considerable promise as a therapeutic option for decreasing cardiovascular disease risk.

1 July 2012 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PMPeter Paul MD
Peter Paul MD
BPBinh An P Phan
Binh An P Phan
TDThomas D Dayspring
Thomas D Dayspring
Peer reviewed article authored by (Phan BAP, Dayspring TD, Toth PP). Read article or submit your manuscript for publishing.

1 September 2011 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
XZXue-Qiao Zhao
Xue-Qiao Zhao
LDLi Dong
Li Dong
THTom Hatsukami
Tom Hatsukami
BPBinh An Phan
Binh An Phan
BCBaocheng Chu
Baocheng Chu
CYChun Yuan
Chun Yuan

1 February 2014 in International Journal of Women's Health
Verified
Journal Article
Open access
PMPeter Paul MD
Peter Paul MD
BPBinh An P Phan
Binh An P Phan
Dyslipidemia is highly prevalent among women. The management of dyslipidemia is a cornerstone in the prevention of both primary and secondary cardiovascular events, such as myocardial infarction, ischemic stroke, and coronary death. All major international guidelines on the treatment of dyslipidemia recommend similar approaches to the management of dyslipidemia in both men and women. Estrogen replacement therapy should not be considered as a therapeutic option for managing dyslipidemia in women. The reduction of atherogenic lipoprotein burden (reducing low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol based on risk-stratified thresholds and treatment targets) provided the framework for managing dyslipidemia in the US, Europe, Canada, and elsewhere in the world. Very recently, new guidelines in the US have changed this paradigm, whereby rather than focusing on treatment targets, risk now defines the intensity of treatment with statin therapy, with no specific goals for what level of low-density lipoprotein cholesterol should be attained. It is not clear if this will lead to changes in lipid guidelines in other parts of the world. In the meantime, region-specific guidelines should be followed. Lipid lowering with statin therapy does correlate with reductions in cardiovascular event rates in women. The clinical impact of treating dyslipidemias in women with nonstatin drugs (eg, fibrates, nicotinic acid, bile acid-binding resins, omega-3 fish oils) is as yet not determined.

1 August 2007 in American Heart Journal
Verified
Journal Article
Closed access
XZXue-Qiao Zhao
Xue-Qiao Zhao
BPBinh An P. Phan
Binh An P. Phan
BCBaocheng Chu
Baocheng Chu
FBFrank Bray
Frank Bray
AMAndrew B. Moore
Andrew B. Moore
CYChun Yuan
Chun Yuan